Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingfei Wu

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Advanced Materials (Deerfield Beach, Fla.)|November 21, 2024
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor ImmunityYuejun Yao, Mingfei Wu, Yanfang Wang, et al.
European Journal of Medicinal Chemistry|June 15, 2024
Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AMLMingfei Wu, Wei Wang, Xinfei Mao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 25, 2024
Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous TumorsYu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 TherapyMingfei Wu, Yiquan Wu, Yuyuan Jin, et al.
European Journal of Medicinal Chemistry|November 27, 2024
Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancerMingfei Wu, Yiming Jiang, Daoming Zhang, et al.
Journal of Medicinal Chemistry|December 6, 2024
Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic AlopeciaXinfei Mao, Weitong Hu, Mingfei Wu, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK DegradationMingfei Wu, Xinfei Mao, Yiquan Wu, et al.
Journal of Medicinal Chemistry|September 30, 2025
Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell LymphomaXiaoli Yu, Xueyan Liao, Jingyu Zhang, et al.
Journal of Medicinal Chemistry|June 7, 2022
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of LymphomaJingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
European Journal of Medicinal Chemistry|November 4, 2024
Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemiaJingyu Zhang, Haiting Duan, Renzhao Gui, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Advanced Materials (Deerfield Beach, Fla.)|November 21, 2024
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor ImmunityYuejun Yao, Mingfei Wu, Yanfang Wang, et al.
European Journal of Medicinal Chemistry|June 15, 2024
Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AMLMingfei Wu, Wei Wang, Xinfei Mao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 25, 2024
Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous TumorsYu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 TherapyMingfei Wu, Yiquan Wu, Yuyuan Jin, et al.
European Journal of Medicinal Chemistry|November 27, 2024
Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancerMingfei Wu, Yiming Jiang, Daoming Zhang, et al.
Journal of Medicinal Chemistry|December 6, 2024
Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic AlopeciaXinfei Mao, Weitong Hu, Mingfei Wu, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK DegradationMingfei Wu, Xinfei Mao, Yiquan Wu, et al.
Journal of Medicinal Chemistry|September 30, 2025
Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell LymphomaXiaoli Yu, Xueyan Liao, Jingyu Zhang, et al.
Journal of Medicinal Chemistry|June 7, 2022
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of LymphomaJingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
European Journal of Medicinal Chemistry|November 4, 2024
Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemiaJingyu Zhang, Haiting Duan, Renzhao Gui, et al.
Pageof 5